Form 4 for PTHS Pelthos Therapeutics Inc.
Accepted 2025-07-03 00:00:00 ET · period of report 2025-07-01 · accession 0000950170-25-093589 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-03 | 2025-07-01 | PTHS | LIGAND PHARMACEUTICALS INC | 10% | C - Cnv Deriv | $10.00 | +1.50M | 1.50M | New | +$15.00M |
| D | 2025-07-03 | 2025-07-01 | PTHS | LIGAND PHARMACEUTICALS INC | 10% | J - Other | — | +31.3K | 34.3K | +1,043% | — |
| D | 2025-07-03 | 2025-07-01 | PTHS | LIGAND PHARMACEUTICALS INC | 10% | C - Cnv Deriv | $0.00 | -15.0K | 3,000 | -83% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-01 | C | A | 1,500,000 | $10.00 | 1,500,000 | D | — | — | (F1) The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. |
| 2 | Derivative | Series A Convertible Preferred Stock | 2025-07-01 | J | A | 31,278.68 | — | 34,278.68 | D | $10.00 · — to — | 3,127,868 Common Stock | (F2) Received in exchange for shares of LNHC, Inc. common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, Inc., a wholly-owned subsidiary of the reporting person, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, the reporting person. (F3) The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. (F1) The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. |
| 3 | Derivative | Series A Convertible Preferred Stock | 2025-07-01 | C | D | 15,000 | $0.00 | 3,000 | D | $10.00 · — to — | 1,500,000 Common Stock | (F3) The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. (F1) The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. |